	US 11,744,809 B2
	Extended release tablet comprising a weight-loss drug
Federico Stroppolo, Aldesago (CH); and Gabriele Granata, Leggiuno (IT)
Assigned to ALPEX PHARMA SA, Mezzovico (CH)
Appl. No. 16/343,914
Filed by ALPEX PHARMA SA, Mezzovico (CH)
PCT Filed Nov. 7, 2017, PCT No. PCT/EP2017/078500 § 371(c)(1), (2) Date Apr. 22, 2019, PCT Pub. No. WO2018/087097, PCT Pub. Date May 17, 2018.
Claims priority of application No. 16197747 (EP), filed on Nov. 8, 2016.
Prior Publication US 2019/0254993 A1, Aug. 22, 2019
Int. Cl. A61K 31/137 (2006.01); A61K 47/36 (2006.01); A61K 47/26 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 9/20 (2006.01); A61P 3/04 (2006.01)

CPC A61K 31/137 (2013.01) [A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2059 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/26 (2013.01); A61K 47/36 (2013.01); A61P 3/04 (2018.01)]

6 Claims

1. An extended release tablet consisting of

a) 1-15% wt. Phentermine HCl;

b) 15-30% wt. hydrophobic excipients consisting of cetostearyl alcohol, stearic acid, and magnesium stearate; and

c) 65-82% wt. hydrophilic excipients consisting of a mixture of maltodextrin and sorbitol;

wherein: i) the ratio of the hydrophilic excipients to the hydrophobic excipients is from 3 to 3.5:1; and ii) the ratio of the maltodextrin to sorbitol in the hydrophilic excipient mixture is 1:1.